Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases

Research output: Contribution to journalJournal articleResearchpeer-review

The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.

Original languageEnglish
JournalDrugs of the Future
Issue number3
Pages (from-to)165-172
Publication statusPublished - 2023

    Research areas

  • Spesolimab, BI-655130, MAB-92, Generalized pustular psoriasis, IL-36R, Monoclonal antibody

ID: 340531009